tion at the time of inclusion (124±10 versus 145±32 mmol/l, P<0.001). Background. There is considerable debate about whether maintenance cyclosporin (CsA) monotherapy Conclusions. Maintenance CsA monotherapy was eÂective in 58% of low-immunological-risk first-graft is advisable or not in renal transplantation. Methods. Between August 1984 and December 1989, patients and probably did not jeopardize overall results of our first grafts: patient and graft survival were 463 adult patients received a first cadaver graft. Initial immunosuppression was sequential: antilymphocyte or respectively 90 and 73% at 6 years. We propose this policy to avoid long-term complications of glucocortantithymocyte globulins (10-14 days), prednisone and azathioprine were combined and CsA was introduced icoid and azathioprine in selected compliant recipients with low immunological risk, follow-up time post-( 6-8 mg/kg/day) when the antilymphocyte or antithymocyte globulins were discontinued. When the graft transplantation >6 months, and stable creatininaemia levels. function was stable and the peak of preformed lymphocytotoxic antibodies was ∏25% and/or the number
were adapted for whole-blood trough levels between Introduction 100 and 200 ng/ml (monoclonal antibody radioimmunoassay or high-performance liquid chromatoMaintenance treatment of first cadaver renal graft is a graphy). Cyclosporin monotherapy was attempted in matter of controversy. There is no ideal immunosup-234 of the 463 patients.
pression. The majority of centres administer long-term Results. At the end of the investigation in January maintenance therapy using low doses of two or three 1993 (follow-up time >36 months, mean 60.5±4. 5 drugs regardless of the characteristics of the recipients months), 135 patients were receiving CsA without or the course of renal transplantation. A few teams steroids or azathioprine. The 99 CsA monotherapy have proposed CsA monotherapy as the maintenance failures were due to rejection episodes in 48 cases, CsA regimen in patients with a stable renal function after A nephrotoxicity in 26 cases, and other causes in 25 initial double or triple therapy, with good patient and cases, including five deaths and four with poor compligraft survivals [1] [2] [3] [4] [5] . The potential advantages of ance. Renal function was stable in patients with sucmaintenance CsA monotherapy are numerous. It cessful CsA monotherapy: mean creatininaemia was avoids complications caused by long-term steroid 124±10 mmol/l at the time of CsA monotherapy incluadministration and overimmunosuppression and hence sion and 129±10 mmol/l at the end of follow-up (mean decreases the incidence of infections and de novo cantime of CsA monotherapy 52±6 months). The paracers. These advantages should be potentially hampered meters for predicting monotherapy success were age by the risks of progressive renal damage due to CsA ( 43.2 versus 37.8, P=0.0014), timing of trial inclusion monotherapy, i.e. the risks of acute and chronic rejec-Á6 months post-transplant (7.9±3 versus 5. previous studies was too small and the duration of above the baseline level at the time of conversion to follow-up was too short. monotherapy.
We therefore designed an open study of maintenance CsA monotherapy in first cadaver kidney transplant Diagnosis of rejection and CsA renal toxicity adult recipients after sequential triple drug initial immunosuppression to specifically answer the followThe diagnosis of acute rejection episodes was based on the ing questions : ( 1) What percentage of first cadaver classical clinical criteria (fever, graft swelling and tenderness, kidney recipients defined as low immunological risk oliguria, weight gain) and on a rapid rise in serum creatinine could be successfully maintained on CsA monother-levels with normal or subtherapeutic trough CsA levels, apy? and (2 ) Which criteria could be used as reliable haematocrit drop, and normal graft appearance by ultrasonopredictors for the outcome of CsA monotherapy? graphy. A graft biopsy was performed when the diagnosis Cyclosporin monotherapy was attempted in a large was not obvious. The diagnosis of CsA renal toxicity relied cohort of informed patients with a good and stable on clinical history, donor age, prolonged graft preservation or anastomosis time, CsA trough level >200 ng/ml by monograft function (creatininaemia <200 mmol/l ), with a clonal antibody immunoassay or high-pressure liquid chrolow immunological risk and a presumably good matography or >600 ng/ml by polyclonal antibody assay, compliance.
gradual rise in serum creatinine with no significant change in haematocrit and a decrease of serum creatinine levels to the initial value after reduction of CsA dosage. The interval monotherapy success (group Ia) were compared to patients with CsA monotherapy failure (group Ib). Statistical com-
Immunosuppressive protocols and inclusion criteria
parisons between value were performed using chi-square analyses for categorical variables and equality of means tests The initial immunosuppressive therapy was similar in all (Student's t test) for comparing groups of continuous varipatients. Rabbit antithymocyte globulins (1.5 mg/kg/day), ables. Graft and patient survival in the diÂerent groups were or horse antilymphocyte globulins ( 3 mg/kg/day)( Institut evaluated by the Kaplan-Meier method [10] . All cases of Mérieux, Lyon, France) from numerous batches were admin-allograft loss were included in the survival analysis. Statistical istered intravenously during 8 to 24 h/day over a 10-14 day significance was defined as a P∏0.05. In the whole series of 463 patients, graft and patient ( 1 mg/kg/day) and azathioprine (2-3 mg/kg/day). Cyclosurvival 6 years after first graft were 73 and 90% sporin A therapy was initiated at the end of globulin therapy at an oral dose of 6-8 mg/kg/day and then adjusted accord-respectively ( Figure 1 ). Cyclosporin monotherapy was ing to the trough whole-blood CsA levels (measured by a attempted in 234 patients i.e. 51% of cases (group I ). radioimmunoassay with polyclonal or monoclonal antibodies The 229 remaining patients were given two-or threeor high-pressure liquid chromatography) to achieve blood drug combination therapy. Main features of the levels of 300-600 ng/ml in the polyclonal antibody assay and patients under study are summarized in Table 1. 100-200 ng/ml in the monoclonal antibody assay and highThe mean follow-up time of patients undergoing pressure liquid chromatography. The prednisone dose (ini-CsA monotherapy (group I ) was 60.5±4.5 months. tially 1 mg/kg/day) was tapered weekly by 10 mg until At the end of follow up, 201 patients were alive with 20 mg/day, then by 5 mg to reach 10 mg/day and then by a functioning graft. Nine patients (4%) died, including 2.5 mg until complete withdrawal of the drug 1.5 to 3 months four patients in haemodialysis and one patient who after grafting. Azathioprine was tapered monthly by 25 mg and then withdrawn between the 3rd and the 12th month received a second graft. Six-year actuarial graft and when graft function was good and stable (creatininaemia patient survival was 80 and 91% respectively. stable and <200 mmol/l ). In case of leukopenia azathioprine At the end of the study 135 patients had functioning was tapered or withdrawn to maintain neutrophils grafts and had receiving neither steroids nor Aza >1500 mm3 and prednisone dose decrease was delayed. (group Ia). They accounted for 58% of the patients Additional inclusion criteria were the occurrence of at most enrolled in the CsA monotherapy trial and 29% of our one acute rejection episode and preformed panel reactive recipients of primary allografts. The mean follow-up antibodies (PRA) below 25%. Patients with either one or time after transplantation and after CsA monotherboth of these criteria were included, whereas those with both apy onset was respectively 59±4.5 months and criteria lacking (i.e. with more than one rejection episode 52±6 months. Seventy-five patients (55.5%) entered and PRA >25%) were excluded. The resumption of prednisone and/or azathioprine (i.e. failure of CsA monotherapy) CsA monotherapy before the 6th month post- month post-transplantation in 59 patients ( 60%). Mean creatininaemia was 145±32 mmol/l at the time of CsA monotherapy onset and 187±20 mmol/l at the time of CsA monotherapy discontinuation. Only three patients (3%) with no preformed anti-HLA antibodies experi- enced more than one rejection episode before CsA monotherapy was tried. sions and number of rejection episodes before CsA Five further patients died with a functional graft. monotherapy onset. Mean creatininaemia at the time Actuarial graft and patient survival at 6 years was 59 of conversion to monotherapy was significantly lower and 79% respectively. Mean follow-up time postin group Ia than in group Ib: 124±10 vs transplantation was 62.5±12 months, and mean 145±32 mmol/l (P<0.001). The number of patients CsA monotherapy duration was 26±13 months. Cyclosporin monotherapy was initiated before the 6th included in CsA monotherapy trial before the 6th month was not statistically diÂerent between the two to 145±32 mmol/l in group Ib patients failing CsA monotherapy (P<0.001). According to other studies, groups: 75 (55.6%) in group Ia vs 59 (60%) in group Ib (P>0.1). However, the mean time of inclusion was we have found CsA well tolerated in terms of graft function in long-term use [5, 8, 9, 11, 12] . Graft function shorter in group Ib (5.3±3.1 months) than in group Ia (7.9±2 months) (P<0.05).
was excellent in group Ia CsA successful patients when no clinical episode of rejection or acute episode of In the department of one of the writers (GT ) mean cyclosporinaemia trough levels ( To) at the time of renal toxicity induced by CsA had occurred with a mean duration of 52±6 months under CsA monotherwithdrawal of steroid was 148±38 ng/ml for 34 patients with CsA monotherapy success versus apy. The timing was also found important in the withdrawal of steroids by Hricik et al. [6 ] . In a recent 143±47 ng/ml for 19 unsuccessful patients; at the time of withdrawal of azathioprine mean To was single-centre analysis of 107 patients treated by CsA plus Aza and withdrawn from steroid therapy; Hricik 144±26 ng/ml versus 149±33 ng/ml. Daily CsA dosage was 5.16±1.14 mg/kg/day versus 5.39±1.21 et al. concluded that the withdrawal of steroids more than 6 months after transplantation resulted in less mg/kg/day respectively at the time of steroid withdrawal ( NS) and 4.86±1.22 versus 6.15±1.42 mg/kg/ acute rejection than in patients undergoing steroid withdrawal within the first post-transplant month. In day, (P=0.05) at the time of Aza withdrawal.
our series the incidence of rejection episodes after initiation of CsA monotherapy was 6% patients per Discussion year of maintenance CsA monotherapy and the incidence of immunologic graft loss was 1.4% patients per year of follow-up post transplantation. The rejection In contrast to previous studies [2] [3] [4] [5] , in this analysis of maintenance CsA monotherapy, the initial immuno-episodes observed after the conversion to monotherapy were usually mild: mean creatininaemia level was suppressive treatment was the same for all recipients and all were cadaver renal allograft recipients. 187±20 mmol/l at the time of CsA discontinuation.
Sixteen kidney grafts were lost secondary to chronic Cyclosporin monotherapy has been applied in 50% of our first grafts, concerning only recipients who were rejection in 99 patients (group Ib) with a mean followup time of 5 years: the incidence of kidney graft loss defined as having 'low immunological risk' and had a stable and good graft function. With a mean follow-was 3.2 per year per cent patients with CsA monotherapy discontinuation. The rejection episodes did not up duration of 60.5±4.5 months, 57% of the patients enrolled in the CsA monotherapy trial were still receiv-occur suddenly after azathioprine withdrawal: the mean maintenance CsA monotherapy duration was ing the same regimen CsA monotherapy. These patients accounted for 29% of all first grafts and 36% of the 26±13 months in group Ib patients.
Cyclosporin monotherapy was used in Europe in functioning first grafts at the end of the follow-up time. A similar rate of CsA monotherapy success in only 1% of recipients of cadaver first-graft within the first week post-transplantation [13] and in only 6.5% first kidney grafts was observed in several series with a shorter duration of follow-up. Tamm et al. [5 ] of 15-44-year-old patients with functioning grafts in December 1988 and grafted in 1986-87-88 as maintenreported their experience with CsA monotherapy during the maintenance phase of well-functioning kid-ance therapy [13] . In our series maintenance CsA monotherapy was applied at the end of follow-up time neys after initial double or triple therapy. Of 171 first transplantations, steroid therapy was completely with-to 35% of functioning cadaveric first grafts and to 58% of functioning cadaveric first grafts defined as low drawn in 99 patients (58%). At the end of the followup 55 patients (55% of the patients undergoing CsA immunological risk. Opelz [14 ] for the Collaborative Transplant Study has shown a more favourable evolumonotherapy and 32% of all analysed patients) were treated by CsA alone. In Tamm's series, the dose of tion at 5 years for patients who had not been treated for rejection during the 1st year and who, after 1 year, steroid was tapered gradually and then discontinued over a period of 4 to 6 months after transplantation if had a serum creatinine concentration <130 mmol/l and were receiving steroid-free maintenance immunosupplasma creatinine values were below 200 mmol/l. Induction therapy was more heterogenous than in our pression with CsA alone or CsA plus Aza during the following 4 years (graft survival 92±1% without series. Cyclosporin monotherapy was successful in 55 of 129 patients (43%) whose kidneys functioned at the steroids versus 87±1% with steroids, P<0.0001). At present some clinical predictors of outcome with mainend of the follow-up. The duration of follow-up after transplantation was at least 12 months (mean 33.4 tenance CsA monotherapy are defined and we think it is eÃcient to begin immunosuppression with sequential months). No prognostic parameters predicting monotherapy success or failure were found in this series. In triple regimen and to decrease the immunosuppression progressively, step by step, to attempt CsA monotherour series we found three predictors of monotherapy success: greater age of recipients, the timing of inclu-apy between 6 months and 1 year post-transplant for 'low immunological risk' and compliant first grafted sion post-transplantation longer than 6 months, and good and stable renal function at initiation of CsA. patients aged >25 years (this limit for the latter criterion is still unprecise and will be further defined ) Serum creatinine concentration at the time of CsA monotherapy initiation was significantly lower in group with good graft function. Further studies are needed to demonstrate a long-term reduction in the risk of de Ia successfully treated by CsA: 124±10 mmol/l versus 
